Literature DB >> 31618015

Tuning Polyamidoamine Design To Increase Uptake and Efficacy of Ruthenium Complexes for Photodynamic Therapy.

Luca Mascheroni1,2, Maria Vittoria Dozzi1, Elisabetta Ranucci1, Paolo Ferruti1, Valentina Francia2, Anna Salvati2, Daniela Maggioni1.   

Abstract

In this work, we report the synthesis of [Ru(phen)32+]-based complexes and their use as photosensitizers for photodynamic therapy (PDT), a treatment of pathological conditions based on the photoactivation of bioactive compounds, which are not harmful in the absence of light irradiation. Of these complexes, Ru-PhenISA and Ru-PhenAN are polymer conjugates containing less than 5%, (on a molar basis), photoactive units. Their performance is compared with that of a small [Ru(phen)32+] compound, [Ru(phen)2BAP](OTf)2 (BAP = 4-(4'-aminobutyl)-1,10-phenanthroline, OTf = triflate anion), used as a model of the photoactive units. The polymer ligands, PhenISA and PhenAN, are polyamidoamines with different acid-base properties. At physiological pH, the former is zwitterionic, the latter moderately cationic, and both intrinsically cytocompatible. The photophysical characterizations show that the complexation to macromolecules does not hamper the Ru(phen)32+ ability to generate toxic singlet oxygen upon irradiation, and phosphorescence lifetimes and quantum yields are similar in all cases. All three compounds are internalized by HeLa cells and can induce cell death upon visible light irradiation. However, their relative PDT efficiency is different: the zwitterionic PhenISA endowed with the Ru-complex lowers the PDT efficiency of the free complex, while conversely, the cationic PhenAN boosts it. Flow cytometry demonstrates that the uptake efficiency of the three agents reflects the observed differences in PDT efficacy. Additionally, intracellular localization studies show that while [Ru(phen)2BAP](OTf)2 remains confined in vesicular structures, Ru-PhenISA localization is hard to determine due to the very low uptake efficiency. Very interestingly, instead, the cationic Ru-PhenAN accumulates inside the nucleus in all treated cells. Overall, the results indicate that the complexation of [Ru(phen)2BAP](OTf)2 with a cationic polyamidoamine to give the Ru-PhenAN complex is an excellent strategy to increase the Ru-complex cell uptake and, additionally, to achieve accumulation at the nuclear level. These unique features together make this compound an excellent photosensitizer with very high PDT efficiency.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31618015     DOI: 10.1021/acs.inorgchem.9b02245

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  4 in total

Review 1.  Factors that influence singlet oxygen formation vs. ligand substitution for light-activated ruthenium anticancer compounds.

Authors:  Elizabeth T Papish; Olaitan E Oladipupo
Journal:  Curr Opin Chem Biol       Date:  2022-04-25       Impact factor: 8.972

2.  Light-Triggered Trafficking to the Cell Nucleus of a Cationic Polyamidoamine Functionalized with Ruthenium Complexes.

Authors:  Luca Mascheroni; Valentina Francia; Beatrice Rossotti; Elisabetta Ranucci; Paolo Ferruti; Daniela Maggioni; Anna Salvati
Journal:  ACS Appl Mater Interfaces       Date:  2020-07-23       Impact factor: 9.229

3.  Nanosized T1 MRI Contrast Agent Based on a Polyamidoamine as Multidentate Gd Ligand.

Authors:  Paolo Arosio; Davide Cicolari; Amedea Manfredi; Francesco Orsini; Alessandro Lascialfari; Elisabetta Ranucci; Paolo Ferruti; Daniela Maggioni
Journal:  Molecules       Date:  2021-12-28       Impact factor: 4.411

Review 4.  Photoactive and Luminescent Transition Metal Complexes as Anticancer Agents: A Guiding Light in the Search for New and Improved Cancer Treatments.

Authors:  Brondwyn S McGhie; Janice R Aldrich-Wright
Journal:  Biomedicines       Date:  2022-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.